Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc

Bullboard Posts

Post by Inca2020on Nov 18, 2020 10:52am

781 Views

Post# 31922025

Question about excerpt from MD&A

Anyone here know why the delay?

Until when?

Here's the excerpt...

"The Company also continues to sell its EAATM diagnostic under the terms of existing commercial arrangements. Previously, the Company anticipated a multi country launch of EAATM with an existing distribution partner in mid Q4 2020, which now has been delayed. Proprietary reagents continue to sell under regular purchase orders as issued by customers. The Company is continuing its efforts in the commercialization of SAMI as well as the development and commercialization of DIMI."

Bullboard Posts

Soma Gold poised to extend profitable track record